Navigation Links
Varian Medical Systems Establishes Radiotherapy Training Center in Mumbai, India
Date:9/1/2010

MUMBAI, India, Sept. 1 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR), a world leader in radiotherapy equipment and software, has established its first education center in India to train medical physicists and technologists working on the company's advanced cancer treatment systems.

The center in Mumbai, equipped with 16 planning system workstations and the VERT* training system for radiotherapy treatment simulations, will enable the country's growing number of radiotherapists and medical physicists to train without having to travel overseas. The official opening, which was attended by Kanta Chokkra, president of the Association of Medical Physicists of India, was carried out by Kolleen Kennedy, Varian's VP Customer Support Services.

"Radiotherapy use is growing rapidly here and we want to do whatever we can to equip the increasing number of practitioners with the experience they need locally," says Michael Sandhu, Varian's regional head of operations. "This training center will give us the opportunity to customize our training solutions to the specific needs of Indian clinicians bringing, in the long term, added value to their practices."

Vivekanand Tathvadkar, Varian's India country manager, adds, "In the current economic climate people are not able to travel as extensively as they used to, so a facility here in India gives them the opportunity to get hands-on experience without leaving the country. We also hope to attract trainees from neighboring countries."

"There are fewer than 400 radiotherapy machines in India and almost half of these are outdated cobalt machines," adds Michael Sandhu, "but we are seeing a rapid investment in new equipment and many Indian hospitals are now able to offer the most advanced treatments available in the world, such as image-guided RapidArc radiotherapy and radiosurgery."  RapidArc® delivers precise image-guided IMRT (intensity modulated radiotherapy) up to four times faster than conventional IMRT.

According to estimates from the Cancer Foundation of India, India has 2 to 2.5 million cancer cases requiring treatment at any point in time and almost a million new cancer cases are diagnosed there each year.  Cancer diagnoses are expected to continue rising in India as the health care system expands and more cases are detected.  

The Mumbai project is the fifth such education and training center established by Varian globally, following similar initiatives in Las Vegas (USA), Beijing (China), Zug (Switzerland) and Buc (France). As well as the education center, Varian's Global Customer Services group is investing in a new parts depot at its Mumbai headquarters, involving a significant investment in ensuring parts and products are readily available locally for customers.    

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

*Trademark of Vertual Ltd.

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,200 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com.


'/>"/>
SOURCE Varian Medical Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 2016  The Parenteral Drug Association, Inc. (PDA), ... manufacturing sterile drug products, today announced the publication ... – With link to Comparison Spreadsheet. The ... U.S. FDA, the EU, the Pharmaceutical Inspection Convention/Scheme ... --> --> PDA,s Global Sterile ...
(Date:2/8/2016)... Feb.8, 2016 Cardiovascular Surgery Devices - ... GlobalData,s Medical Devices sector report, "Cardiovascular Surgery Devices ... overview of Cardiovascular Surgery Devices currently in pipeline ... The report provides comprehensive information on the ... at various stages of development. The report reviews ...
(Date:2/8/2016)... FAIRFIELD, N.J. , Feb. 8, 2016  Otsuka ... today announced that they have entered into a licensing ... OPA-15406 in the U.S. and Puerto Rico ... is a topical, non-steroidal phosphodiesterase IV (PDE-4) inhibitor, a ... --> --> In a Phase II ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... A man who has struggled to quit smoking, a man who has ... determined to find solutions to his problems – and he did. Now Nabat, a serial ... to introduce his breakthrough inventions to the world and better people's lives. His own experience ...
(Date:2/8/2016)... Hilton Head Island, SC (PRWEB) , ... February 08, 2016 , ... ... Head and surrounding areas with a vital new community enrichment program, has teamed up ... to local women and children suffering from intimate abuse. To support all those victimized ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... today that nominations will be accepted February 8, 2016 through May 8, ... Awards include the Information Security Executive® of the Year, which recognizes executives ...
(Date:2/8/2016)... ... February 08, 2016 , ... Discover the Rocky Mountain region’s longest ... and 700 companies. Attendees also get to see the most incredible gardens and ... Home Show , at the Colorado Convention Center - 700 14th St. Denver CO, ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... speaking on how healthcare companies can use newly released government data on populations ... a population and intervene and capture the value they create to succeed in ...
Breaking Medicine News(10 mins):